484 related articles for article (PubMed ID: 25172549)
1. Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28.
Le PN; McDermott JD; Jimeno A
Pharmacol Ther; 2015 Feb; 146():1-11. PubMed ID: 25172549
[TBL] [Abstract][Full Text] [Related]
2. A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors.
Jimeno A; Gordon M; Chugh R; Messersmith W; Mendelson D; Dupont J; Stagg R; Kapoun AM; Xu L; Uttamsingh S; Brachmann RK; Smith DC
Clin Cancer Res; 2017 Dec; 23(24):7490-7497. PubMed ID: 28954784
[No Abstract] [Full Text] [Related]
3. Frizzled Receptors in Tumors, Focusing on Signaling, Roles, Modulation Mechanisms, and Targeted Therapies.
Sun Y; Wang W; Zhao C
Oncol Res; 2021 Mar; 28(6):661-674. PubMed ID: 32998794
[TBL] [Abstract][Full Text] [Related]
4. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors.
Gurney A; Axelrod F; Bond CJ; Cain J; Chartier C; Donigan L; Fischer M; Chaudhari A; Ji M; Kapoun AM; Lam A; Lazetic S; Ma S; Mitra S; Park IK; Pickell K; Sato A; Satyal S; Stroud M; Tran H; Yen WC; Lewicki J; Hoey T
Proc Natl Acad Sci U S A; 2012 Jul; 109(29):11717-22. PubMed ID: 22753465
[TBL] [Abstract][Full Text] [Related]
5. Molecular genetics and targeted therapy of WNT-related human diseases (Review).
Katoh M; Katoh M
Int J Mol Med; 2017 Sep; 40(3):587-606. PubMed ID: 28731148
[TBL] [Abstract][Full Text] [Related]
6. Targeting the WNT Signaling Pathway in Cancer Therapeutics.
Tai D; Wells K; Arcaroli J; Vanderbilt C; Aisner DL; Messersmith WA; Lieu CH
Oncologist; 2015 Oct; 20(10):1189-98. PubMed ID: 26306903
[TBL] [Abstract][Full Text] [Related]
7. Wnt pathway modulators in cancer therapeutics: An update on completed and ongoing clinical trials.
Neiheisel A; Kaur M; Ma N; Havard P; Shenoy AK
Int J Cancer; 2022 Mar; 150(5):727-740. PubMed ID: 34536299
[TBL] [Abstract][Full Text] [Related]
8. A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
Moore KN; Gunderson CC; Sabbatini P; McMeekin DS; Mantia-Smaldone G; Burger RA; Morgan MA; Kapoun AM; Brachmann RK; Stagg R; Farooki A; O'Cearbhaill RE
Gynecol Oncol; 2019 Aug; 154(2):294-301. PubMed ID: 31174889
[TBL] [Abstract][Full Text] [Related]
9. The Wnt signaling pathway in cancer.
Duchartre Y; Kim YM; Kahn M
Crit Rev Oncol Hematol; 2016 Mar; 99():141-9. PubMed ID: 26775730
[TBL] [Abstract][Full Text] [Related]
10. Wnt signaling dynamics in head and neck squamous cell cancer tumor-stroma interactions.
Le PN; Keysar SB; Miller B; Eagles JR; Chimed TS; Reisinger J; Gomez KE; Nieto C; Jackson BC; Somerset HL; Morton JJ; Wang XJ; Jimeno A
Mol Carcinog; 2019 Mar; 58(3):398-410. PubMed ID: 30378175
[TBL] [Abstract][Full Text] [Related]
11. The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo.
DeAlmeida VI; Miao L; Ernst JA; Koeppen H; Polakis P; Rubinfeld B
Cancer Res; 2007 Jun; 67(11):5371-9. PubMed ID: 17545618
[TBL] [Abstract][Full Text] [Related]
12. Frizzled Receptors as Potential Therapeutic Targets in Human Cancers.
Zeng CM; Chen Z; Fu L
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29789460
[TBL] [Abstract][Full Text] [Related]
13. Small-molecule inhibitors of Wnt signaling pathway: towards novel anticancer therapeutics.
Zheng S; Liu J; Wu Y; Huang TL; Wang G
Future Med Chem; 2015; 7(18):2485-505. PubMed ID: 26670195
[TBL] [Abstract][Full Text] [Related]
14. Structure-based Discovery of Novel Small Molecule Wnt Signaling Inhibitors by Targeting the Cysteine-rich Domain of Frizzled.
Lee HJ; Bao J; Miller A; Zhang C; Wu J; Baday YC; Guibao C; Li L; Wu D; Zheng JJ
J Biol Chem; 2015 Dec; 290(51):30596-606. PubMed ID: 26504084
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Wnt/β-catenin signaling pathway in cancer.
Zhang Y; Wang X
J Hematol Oncol; 2020 Dec; 13(1):165. PubMed ID: 33276800
[TBL] [Abstract][Full Text] [Related]
16. Targeting the Wnt/β-catenin signaling pathway in human cancers.
Yao H; Ashihara E; Maekawa T
Expert Opin Ther Targets; 2011 Jul; 15(7):873-87. PubMed ID: 21486121
[TBL] [Abstract][Full Text] [Related]
17. Discovery and characterization of a potent Wnt and hedgehog signaling pathways dual inhibitor.
Ma H; Chen Q; Zhu F; Zheng J; Li J; Zhang H; Chen S; Xing H; Luo L; Zheng LT; He S; Zhang X
Eur J Med Chem; 2018 Apr; 149():110-121. PubMed ID: 29499483
[TBL] [Abstract][Full Text] [Related]
18. Targeting Wnts at the source--new mechanisms, new biomarkers, new drugs.
Madan B; Virshup DM
Mol Cancer Ther; 2015 May; 14(5):1087-94. PubMed ID: 25901018
[TBL] [Abstract][Full Text] [Related]
19. Wnt Signaling and Drug Resistance in Cancer.
Zhong Z; Virshup DM
Mol Pharmacol; 2020 Feb; 97(2):72-89. PubMed ID: 31787618
[TBL] [Abstract][Full Text] [Related]
20. Recent updates on Wnt signaling modulators: a patent review (2014-2020).
Goswami VG; Patel BD
Expert Opin Ther Pat; 2021 Nov; 31(11):1009-1043. PubMed ID: 34128760
[No Abstract] [Full Text] [Related]
[Next] [New Search]
